REG - Cizzle Biotechnology - £250,000 Convertible Loan Note Issue

Cizzle Biotechnology HoldingsAnnouncement

05/11/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251105:nRSE1974Ga&default-theme=true

RNS Number : 1974G  Cizzle Biotechnology Holdings PLC  05 November 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR")

5 November 2025

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

£250,000 Convertible Loan Note Issue

Cizzle Biotechnology, the UK based diagnostics developer of early cancer
tests, is pleased to announce that it has raised up to £250,000 through the
issue of further unsecured convertible loan notes ("Additional Notes") to
Frazer Lang, an existing investor in the Company.

On 20 May 2025, the Company secured funding of £150,000 through the issue of
convertible loan notes ("Original Notes") from the Company's existing
shareholder, Frazer Lang to provide additional funding to support the
Company's growth strategy, in particular to roll out its CIZ1B biomarker test
to help detect lung cancer early in the UK and elsewhere in Europe.  Today,
the Company announced that it has entered into a Letter of Intent ("LOI") with
a leading medical diagnostic services provider (the "Provider") acting in
partnership with the NHS as result of that initiative.

The Additional Notes will be issued as an extension to the Company's existing
unsecured convertible loan notes of £150,000 ("Original Notes") issued to
Frazer Lang (the "Note Holder"), on 18 May 2025. The Company may issue the
Additional Notes at £50,000 per month and any funds received will be used in
connection with the Company's focus on commercialising its CIZ1B biomarker
test in North America and the UK.  Any Additional Notes issued are
convertible at any time up to 31 March 2026, at the election of the Note
Holder, into new ordinary shares of 0.01p in the Company ("Ordinary Shares")
at a price of 1.4 pence per ordinary share.  No interest or fees are payable
on the Additional Notes.

Prior to 31 March 2026 the Company does not intend to incur any debt (other
than in the ordinary course of business) or make any adjustments to its share
capital while the Additional Notes are outstanding.  Frazer Lang has
committed to only redeem the Original Notes and Additional Notes for ordinary
shares and not seek any cash repayment.

The Company has also issued warrants to Frazer Lang over 12,500,000 Ordinary
Shares in the Company at an exercise price of 2p, to be exercised within two
years of the date of issue.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"The Company is making excellent progress in finding key partners to roll out
our proprietary CIZ1B biomarker test that can help in early lung cancer
detection.  With an established route to market in North America and the
Caribbean, we are committed to ensure that patients in the UK and elsewhere in
Europe will also have access to a simple, non-invasive means to find cancer
early when curative intervention is possible.  Securing ongoing support from
all our shareholders is critical in this journey and we want to thank in
particular the significant investment and support we have received from Frazer
Lang and his family.  The further funding being received from Mr Lang
provides important capital to accelerate our plans for growth and to make the
test available to as many patients as soon as possible.  In addition to the
new programme in the UK, the Company will also continue to support its US
partner Cizzle BIO Inc, to secure CLIA accreditation to take the test live in
the near term, and to complete the ongoing Moffitt study to test patients with
suspicious lung nodules in a clinical evaluation, as announced on 9 September
2024."

Commenting, Frazer Lang said:

"I am delighted to extend my support for Cizzle through this additional
funding, building on my existing shareholding.  The Company's progress in
partnering with world-class organisations underscores the transformative
potential of the CIZ1B test in early lung cancer detection.  I remain fully
committed to Cizzle's mission and look forward to seeing the test benefit
patients across the UK, Europe, and beyond."

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                               +44(0) 20 3328 5656
 John Depasquale / Piers Shimwell (Corporate Finance)
 Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited            +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

 

The CIZ1B biomarker test for early-stage lung cancer is based on the
pioneering work of Professor Coverley, the Founder and CSO of the Company, and
her research team at the University of York. CIZ1 is a naturally occurring
cell nuclear protein and the CIZ1B variant form is highly associated with the
presence of early-stage lung cancer. The Company has developed CIZ1B into a
non-invasive, cost-effective blood test to help in the diagnosis and detection
of lung cancer and has now entered commercial royalty-bearing arrangements to
license its proprietary technology, and into collaborations with centres of
excellence in cancer care.  Cizzle was admitted to trading on the Main Market
of the London Stock Exchange in May 2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

 

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODDGBDBGSGDGUS



            Copyright 2019 Regulatory News Service, all rights reserved